Combined modality treatment for early-stage Hodgkin’s lymphoma: the GHSG experience

S Sasse; V Diehl; A Engert

doi:10.4081/hmr.v2i7.402

Authors

The prognosis of patients has substantially improved over the last decades. Currently, approximately 80% of all patients remain disease free 5 years after treatment.1 On the basis of clinical staging and risk factors as listed in Table 1 patients with Hodgkin lymphoma (HL) are usually classified into early favourable stages (CS 1-2 without risk factors), early-unfavorable stages (CS I-II with risk factors) or advanced stages. Here, we report on the experience of the GHSG and others in the treatment of early favourable and unfavourable HL.

Supporting Agencies

Sasse, S., Diehl, V., & Engert, A. (2009). Combined modality treatment for early-stage Hodgkin’s lymphoma: the GHSG experience. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.402

Download Citation

Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Downloads

Citations